Home/ Stocks/ ACTU

Actuate Therapeutics, Inc. Common stock

ACTU XNAS

$1.10 -0.09 (-7.32%) ▼ 15-min delayed

Open

$1.24

High

$1.25

Low

$1.10

Volume

203.6K

Market Cap

$29.43M

About Actuate Therapeutics, Inc. Common stock

Actuate Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing therapies for the treatment of high impact, difficult to treat cancers through the inhibition of glycogen synthase kinase-3 (GSK-3). It is developing elraglusib (formerly 9-ING-41), a small molecule that is designed to enter cancer cells and block the function of the enzyme GSK-3B, a master regulator of complex biological signaling cascades, including those mediated by oncogenes, that lead to tumor cell survival, growth, migration, and invasion.

Sector: PHARMACEUTICAL PREPARATIONS Employees: 12 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q1 2026	$0	$-5,625,749	$-0.24
FY 2025	$0	$-22,227,852	$-1.06
Q3 2025	$0	$-5,407,470	$-0.25
Q2 2025	$0	$-5,949,405	$-0.30

Related Market News

No specific coverage for ACTU yet. Check out our latest market news or earnings calendar.

Get ACTU Alerts

Stay ahead with breaking news, price alerts, and expert analysis on Actuate Therapeutics, Inc. Common stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.